"description","label","uuid:ID","instanceType","name","rationale","id"
"The main design for the study","","f6a00733-3522-4cdd-8f07-34cde93da388","StudyDesign","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
